ArticleStem cells translational medicine2026
HO-1-modified umbilical cord MSCs alleviate pulmonary arterial hypertension by reducing inflammation and endothelial dysfunction.
Article in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo evaluate the efficacy of MSCs-HO-1 in pulmonary arterial hypertension (PAH) and explore the underlying mechanisms.
methodsHO-1 expression and localization in lung tissues and vessels were assessed using spatial transcriptomics and single-cell RNA sequencing analyses of human PAH. MSCs-HO-1 were intravenously administered in rat and mouse PAH models (MCT-induced and SuHx). Hemodynamics (RVSP), right ventricular hypertrophy index (RVHI), survival rate, and vascular remodeling were assessed by HE staining and α-SMA immunostaining. Inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-18, IL-10, TGF-β, IL-4, IL-1Ra), ROS levels, and endothelial molecules [nitric oxide (NO) and prostaglandin I2 (PGI2)] were measured. RNA sequencing (RNA-seq) of PAECs was followed by pathway analysis and MAPK validation.
resultsHO-1 was downregulated in PAH patients and models, mainly in the vascular endothelium. MSCs-HO-1 significantly reduced RVSP, RVHI, vascular remodeling, and improved survival compared to unmodified MSCs and HO-1 alone. MSCs-HO-1 inhibited pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-18), increased anti-inflammatory factors (IL-10, TGF-β, IL-4, IL-1Ra), reduced ROS, and restored NO/PGI2. PAEC migration and proliferation abnormalities were corrected. RNA-seq revealed multiple synergistic pathways, with MAPK playing a key role in endothelial protection.
conclusionMSCs-HO-1 enhances endothelial function and pulmonary vascular remodeling by modulating antioxidant and immune responses, restoring NO-PGI2 signaling, and suppressing MAPK-mediated inflammation, providing more stable and significant effects than MSCs or HO-1 alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.